Evidence map›Paper›PMID 38474022›Full record

ArticleInternational journal of molecular sciences2024

Enhanced Antioxidant and Neuroprotective Properties of Pterostilbene (Resveratrol Derivative) in Amorphous Solid Dispersions.

Natalia Rosiak, Ewa Tykarska, Judyta Cielecka-Piontek

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Review
  3. Myricetin Nanofibers as Amorphous Delivery System.Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Cyclodextrin/PVP-Based Nanofibers withMolecules (Basel, Switzerland) · 2025
    Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Natalia RosiakDepartment of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznan, Poland.ORCID 0000-0003-4722-6413
Ewa TykarskaDepartment of Chemical Technology of Drugs, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznan, Poland.ORCID 0000-0001-9393-3536
Judyta Cielecka-PiontekDepartment of Pharmacognosy and Biomaterials, Faculty of Pharmacy, Poznan University of Medical Sciences, 3 Rokietnicka St., 60-806 Poznan, Poland.ORCID 0000-0003-0891-5419

Funding

National Science Center UMO-2020/37/B/NZ7/03975
6 · The paper itself

Abstract

In this study, amorphous solid dispersions (ASDs) of pterostilbene (PTR) with polyvinylpyrrolidone polymers (PVP K30 and VA64) were prepared through milling, affirming the amorphous dispersion of PTR via X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC). Subsequent analysis of DSC thermograms, augmented using mathematical equations such as the Gordon-Taylor and Couchman-Karasz equations, facilitated the determination of predicted values for glass transition (T

Indexed as

AntioxidantsBenzothiazolesPovidoneSulfonic AcidsCalorimetry, Differential ScanningPolymersResveratrolSolubilitySpectroscopy, Fourier Transform InfraredWaterX-Ray Diffraction2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acidAntioxidantsBenzothiazolesPolymersPovidoneResveratrolSulfonic AcidsWateramorphous solid dispersionantioxidationCouchman–Karasz equationglass transitionGordon–Taylor equationmiscibilitymolecular modelingneuroprotectionpolyvinylpyrrolidonepterostilbene

Identifiers

PMID38474022
PMCPMC10932125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.